{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:34:40Z","timestamp":1793406880690,"version":"4.5.0"},"reference-count":44,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T00:00:00Z","timestamp":1733788800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>The recent EMPA-KIDNEY trial showed evidence for preventing disease progression in adult patients with chronic kidney disease (CKD) treated with empagliflozin. It is however yet unknown if use of empagliflozin is cost effective in the Netherlands. We aimed to evaluate the cost effectiveness of empagliflozin in adult patients with CKD in the Netherlands.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A cost-effectiveness analysis was conducted using a Markov state microsimulation model, simulating kidney progression of CKD patients with eGFR &lt;90 ml\/min per 1.73 m2 comparing empagliflozin plus standard of care (SoC) and SoC alone. KDIGO classification was used to describe the risk of CKD progression. The input data were taken from the EMPA-KIDNEY trial (baseline characteristics, treatment effect, and utilities), and published data and national sources were used for general population mortality, treatment and event costs. The analyses were performed from a societal perspective with applying a lifetime horizon. Discounting was done according to the Dutch pharmacoeconomic guidelines. The incremental cost-effectiveness ratio (ICER) was compared to a willingness-to-pay threshold of \u20ac50,000\/QALY. Deterministic and probabilistic sensitivity analyses were performed to explore the impact of uncertainty around the input parameters.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The base-case results showed total discounted costs for empagliflozin plus SoC and SoC alone of \u20ac200,193 and \u20ac234,574 respectively, indicating total savings of \u20ac34,380. Empagliflozin plus SoC was associated with higher total discounted health benefits of 11.06 life years (LYs) and 9.01 quality-adjusted life years (QALYs), compared with 9.74 LYs and 7.79 QALYs for SoC alone, resulting in an additional 1.31 LYs and 1.22 QALYs for empagliflozin plus SoC. Empagliflozin plus SoC is a dominant alternative compared to SoC alone. Sensitivity analyses confirmed the robustness of the findings and conclusion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Using empagliflozin in addition to SoC in adult patients with CKD is likely to be cost saving compared to the current SoC in the Netherlands, irrespective of diabetes status and albuminuria.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0315509","type":"journal-article","created":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T13:31:11Z","timestamp":1733837471000},"page":"e0315509","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cost effectiveness of empagliflozin in adult patients with chronic kidney disease in the Netherlands"],"prefix":"10.1371","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-9125-0190","authenticated-orcid":true,"given":"Bart","family":"Slob","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3995-447X","authenticated-orcid":true,"given":"Tanja","family":"Fens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maaike","family":"Weersma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten","family":"Postma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelis","family":"Boersma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,12,10]]},"reference":[{"key":"pone.0315509.ref001","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease","volume":"105","author":"PE Stevens","year":"2024","journal-title":"Kidney Int"},{"key":"pone.0315509.ref002","author":"W De Grauw","year":"2018","journal-title":"NHG-Standaard-Chronische nierschade"},{"key":"pone.0315509.ref003","unstructured":"Kidney Disease Surveillance System. [cited 2023 Oct 20]. Available from: https:\/\/nccd.cdc.gov\/ckd\/default.aspx"},{"key":"pone.0315509.ref004","article-title":"Chronic kidney disease: assessment and management","author":"NICE guideline.","year":"2021"},{"key":"pone.0315509.ref005","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.kint.2019.04.021","article-title":"Mitochondrial DNA copy number is associated with mortality and infections in a large cohort of patients with chronic kidney disease","volume":"96","author":"F Fazzini","year":"2019","journal-title":"Kidney Int"},{"key":"pone.0315509.ref006","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, regional, and national burden of chronic kidney disease, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"395","author":"GBD Chronic Kidney Disease Collaboration","year":"2020","journal-title":"Lancet Lond Engl"},{"key":"pone.0315509.ref007","unstructured":"Annual Data Report. U. S. Ren. Data Syst. USRDS. [cited 2023 Oct 20]. Available from: https:\/\/adr.usrds.org\/"},{"key":"pone.0315509.ref008","article-title":"Chronische nierschade | NHG-Richtlijnen","author":"Nederlandse Huisartsen Genootschap)."},{"key":"pone.0315509.ref009","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s11255-013-0563-3","article-title":"A population-based study on the prevalence and incidence of chronic kidney disease in the Netherlands.","volume":"46","author":"JC van Blijderveen","year":"2014","journal-title":"Int Urol Nephrol"},{"key":"pone.0315509.ref010","doi-asserted-by":"crossref","first-page":"e964","DOI":"10.1097\/MD.0000000000000964","article-title":"Severity of Anemia Predicts Hospital Length of Stay but Not Readmission in Patients with Chronic Kidney Disease: A Retrospective Cohort Study.","volume":"94","author":"K Garlo","year":"2015","journal-title":"Medicine (Baltimore)."},{"key":"pone.0315509.ref011","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1093\/ckj\/sfab070","article-title":"Fighting the unbearable lightness of neglecting kidney health: the decade of the kidney.","volume":"14","author":"R Vanholder","year":"2021","journal-title":"Clin Kidney J"},{"key":"pone.0315509.ref012","unstructured":"Nierstichting. Feiten en cijfers. Nierstichting. [cited 2023 Dec 15]. Available from: https:\/\/nierstichting.nl\/leven-met-een-nierziekte\/feiten-en-cijfers\/"},{"key":"pone.0315509.ref013","unstructured":"KNOTEK HV Ond\u0159ej. Parliamentary question | A systematic EU approach to chronic kidney disease | O-000005\/2022 | European Parliament [Internet]. [cited 2023 Nov 3]. Available from: https:\/\/www.europarl.europa.eu\/doceo\/document\/O-9-2022-000005_EN.html"},{"key":"pone.0315509.ref014","article-title":"Diabetes mellitus type 2 | NHG-Richtlijnen.","author":"Nederlandse Huisartsen Genootschap."},{"key":"pone.0315509.ref015","unstructured":"Richtlijnen | Nederlandse Federatie voor Nefrologie. [cited 2024 Feb 28]. Available from: https:\/\/www.nefro.nl\/richtlijnen"},{"key":"pone.0315509.ref016","unstructured":"Jardiance | European Medicines Agency. [cited 2023 Oct 20]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/jardiance"},{"key":"pone.0315509.ref017","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in Patients with Chronic Kidney Disease","volume":"388","author":"W.G Herrington","year":"2023","journal-title":"N Engl J Med"},{"key":"pone.0315509.ref018","volume-title":"GVS-advies empagliflozine (Jardiance\u00ae) uitbreiding bijlage 2-voorwaarden voor chronische nierschade\u2014Advies\u2014Zorginstituut Nederland.","author":"National Health Care Institute W en S","year":"2023"},{"key":"pone.0315509.ref019","volume-title":"GVS-advies uitbreiding bijlage 2-voorwaarden dapagliflozine (Forxiga\u00ae) bij de behandeling van chronische nierschade\u2014Advies\u2014Zorginstituut Nederland","author":"National Health Care Institute W en S","year":"2022"},{"key":"pone.0315509.ref020","volume-title":"Guideline for conducting economic evaluations in health care.","author":"National Health Care Institute","year":"2016"},{"key":"pone.0315509.ref021","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12916-021-02204-0","article-title":"Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.","volume":"20","author":"D Husereau","year":"2022","journal-title":"BMC Med."},{"key":"pone.0315509.ref022","volume-title":"Centraal Bureau voor de Statistiek.","author":"Statistiek CB voor de","year":"2023"},{"key":"pone.0315509.ref023","doi-asserted-by":"crossref","first-page":"100552","DOI":"10.1016\/j.eclinm.2020.100552","article-title":"Incorporating kidney disease measures into cardiovascular risk prediction: Development and validation in 9 million adults from 72 datasets.","volume":"27","author":"K Matsushita","year":"2020","journal-title":"EClinicalMedicine"},{"key":"pone.0315509.ref024","unstructured":"| The UK Kidney Associatio. UKRR. 24th UKRR Annual Report. [cited 2023 Dec 15]. Available from: https:\/\/ukkidney.org\/audit-research\/annual-report\/24th-annual-report-data-31122020."},{"key":"pone.0315509.ref025","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/j.1524-4733.2007.00308.x","article-title":"Preference-based quality of life of patients on renal replacement therapy: a systematic review and meta-analysis.","volume":"11","author":"YS Liem","year":"2008","journal-title":"Value Health J Int Soc Pharmacoeconomics Outcomes Res"},{"key":"pone.0315509.ref026","article-title":"Single Technology Appraisal Dapagliflozin for treating chronic kidney disease [ID3866].","author":"National Institute for Health and Care Excellence","year":"2023"},{"key":"pone.0315509.ref027","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/hec.4008","article-title":"Comparing the EQ\u20105D\u20105L crosswalks and value sets for England, the Netherlands and Spain: Exploring their impact on cost\u2010utility results.","volume":"29","author":"\u00c2 Ben","year":"2020","journal-title":"Health Econ."},{"key":"pone.0315509.ref028","unstructured":"Z-Index. [cited 2024 Jan 26]. Available from: https:\/\/www.z-index.nl\/"},{"key":"pone.0315509.ref029","unstructured":"National Health Care Institute. Kosteneffectiviteit in de praktijk\u2014Rapport. Ministerie van Volksgezondheid, Welzijn en Sport; 2015 [cited 2024 Mar 8]. Available from: https:\/\/www.zorginstituutnederland.nl\/publicaties\/rapport\/2015\/06\/26\/kosteneffectiviteit-in-de-praktijk"},{"key":"pone.0315509.ref030","doi-asserted-by":"crossref","first-page":"100438","DOI":"10.1016\/j.lanepe.2022.100438","article-title":"Prevalence, outcomes, and cost of chronic kidney disease in a contemporary population of 2\u00b74 million patients from 11 countries: The CaReMe CKD study","volume":"20","author":"J Sundstr\u00f6m","year":"2022","journal-title":"Lancet Reg Health Eur"},{"key":"pone.0315509.ref031","doi-asserted-by":"crossref","first-page":"e0165675","DOI":"10.1371\/journal.pone.0165675","article-title":"Health-Related Quality of Life Impacts Mortality but Not Progression to End-Stage Renal Disease in Pre-Dialysis Chronic Kidney Disease: A Prospective Observational Study.","volume":"11","author":"MD Jesky","year":"2016","journal-title":"PloS One"},{"key":"pone.0315509.ref032","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1080\/13696998.2024.2368990","article-title":"Cost-effectiveness of add-on empagliflozin versus standard of care in management of CKD in Malaysia, Thailand and Vietnam\u2014findings from a modelling study assessing an EMPA-KIDNEY eligible population, using CKD progression model.","volume":"27","author":"L Varghese","year":"2024","journal-title":"J Med Econ."},{"key":"pone.0315509.ref033","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1080\/13696998.2024.2357041","article-title":"Cost-effectiveness of empagliflozin as add-on to standard of care for chronic kidney disease management in the United Kingdom.","volume":"27","author":"M Ramos","year":"2024","journal-title":"J Med Econ"},{"key":"pone.0315509.ref034","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","author":"C Baigent","year":"2022","journal-title":"The Lancet"},{"key":"pone.0315509.ref035","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.2215\/CJN.03790322","article-title":"Cost-Effectiveness of Dapagliflozin as a Treatment for Chronic Kidney Disease","volume":"17","author":"P McEwan","year":"2022","journal-title":"Clin J Am Soc Nephrol CJASN"},{"key":"pone.0315509.ref036","doi-asserted-by":"crossref","first-page":"3030","DOI":"10.1111\/dom.15201","article-title":"Cost-effectiveness of canagliflozin and dapagliflozin for treatment of patients with chronic kidney disease and type 2 diabetes","volume":"25","author":"B-N Nguyen","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"pone.0315509.ref037","doi-asserted-by":"crossref","first-page":"3380","DOI":"10.1007\/s11606-021-07311-5","article-title":"Cost-Effectiveness of Dapagliflozin for Non-diabetic Chronic Kidney Disease.","volume":"37","author":"RL Tisdale","year":"2022","journal-title":"J Gen Intern Med"},{"key":"pone.0315509.ref038","doi-asserted-by":"crossref","first-page":"107761","DOI":"10.1016\/j.jdiacomp.2020.107761","article-title":"SGLT-2 inhibitors may be targeting higher risk patients with diabetes possibly justifying higher cost: Single center repeated cross-sectional analysis","volume":"35","author":"LA Weinrauch","year":"2021","journal-title":"J Diabetes Complications"},{"key":"pone.0315509.ref039","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1186\/s12933-023-02053-6","article-title":"Cost-effectiveness of finerenone in chronic kidney disease associated with type 2 diabetes","volume":"22","author":"SW Quist","year":"2023","journal-title":"The Netherlands. Cardiovasc Diabetol"},{"key":"pone.0315509.ref040","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1185\/030079908X253410","article-title":"Utility of health states in chronic kidney disease: a structured review of the literature.","volume":"24","author":"PL Dale","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"pone.0315509.ref041","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1080\/14737167.2017.1331432","article-title":"The influence of time horizon on results of cost-effectiveness analyses.","volume":"17","author":"DD Kim","year":"2017","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"pone.0315509.ref042","first-page":"2138","article-title":"Age-related difference in health care use and costs of patients with chronic kidney disease and matched controls: analysis of Dutch health care claims data.","volume":"35","author":"MJM van Oosten","year":"2020","journal-title":"Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc\u2014Eur Ren Assoc"},{"key":"pone.0315509.ref043","first-page":"1685","article-title":"Clinical events and patient-reported outcome measures during CKD progression: findings from the Chronic Renal Insufficiency Cohort Study.","volume":"36","author":"ME Grams","year":"2021","journal-title":"Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc\u2014Eur Ren Assoc"},{"key":"pone.0315509.ref044","doi-asserted-by":"crossref","first-page":"102414","DOI":"10.1016\/j.eclinm.2023.102414","article-title":"Cost-effectiveness of home-based screening of the general population for albuminuria to prevent progression of cardiovascular and kidney disease.","volume":"68","author":"XGLV Pouwels","year":"2024","journal-title":"eClinicalMedicine."}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0315509","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T13:31:37Z","timestamp":1733837497000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0315509"}},"subtitle":[],"editor":[{"given":"Larry Allan","family":"Weinrauch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,12,10]]},"references-count":44,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12,10]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0315509","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,10]]}}}